Key clinical point: A survey suggests the elementary nature of follow-up practices and substantial differences in patient eligibility criteria are key issues with CAR T-cell therapy.
Major finding: Among respondents, no agreement was reached on whether central nervous system involvement was a valid exclusion parameter and there remains no standard model of care for patient follow-up.
Study details: An international survey of 41 physicians with experience using CAR T-cell therapies for diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia.
Disclosures: The study was funded by the European Society for Blood and Marrow Transplantation.
Hayden PJ et al. Curr Res Transl Med. 2019 Aug;67(3):79-88.